Clinical Trials Sponsored by Rovi Pharmaceuticals Laboratories

Total 183 results

Rovi Pharmaceuticals Laboratories

Recruiting

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (QUARTZ)

Schizophrenia

Jordan
Rovi Pharmaceuticals Laboratories

Active, not recruiting

Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)

Healthy

Czechia
Rovi Pharmaceuticals Laboratories

Completed

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension (PRISMA-3_OLE)

Schizophrenia

United States, Ukraine
Rovi Pharmaceuticals Laboratories

Completed

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia (PRISMA-3)

Acute Schizophrenia

United States, Ukraine
Rovi Pharmaceuticals Laboratories

Recruiting

Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women (LEILA-1)

Healthy

Czechia
Rovi Pharmaceuticals Laboratories

Recruiting

Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse (RESHAPE)

Schizophrenia

Germany
Rovi Pharmaceuticals Laboratories

Completed

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (PRISMA-1)

Schizophrenia | Schizoaffective Disorder

Spain, South Africa, Russian Federation, Croatia
Rovi Pharmaceuticals Laboratories

Completed

Comparative Bioavailability of Risperidone.

Schizophrenia

United States
Rovi Pharmaceuticals Laboratories

Completed

Comparative Bioavailability of Risperidone

Schizophrenia

United States
Rovi Pharmaceuticals Laboratories

Completed

Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers

Healthy

Spain
Rovi Pharmaceuticals Laboratories

Completed

Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly

Renal Insufficiency

Spain
Rovi Pharmaceuticals Laboratories

Completed

Pharmacokinetic Study of Two Oral Bemiparin Formulations

Healthy

Spain
Rovi Pharmaceuticals Laboratories

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers

Foot Ulcer, Diabetic

Croatia, Poland, Romania, Russian Federation, Serbia, Spain
Rovi Pharmaceuticals Laboratories

Completed

Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia (PRISMA-2)

Schizophrenia

United States
Rovi Pharmaceuticals Laboratories

Completed

Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM®

Healthy
Rovi Pharmaceuticals Laboratories

Completed

CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)

Cancer | Venous Thromboembolism

Spain, Portugal, Romania, Russian Federation
Rovi Pharmaceuticals Laboratories
PRA Health Sciences

Completed

Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers

Healthy
Spanish National Health System
Carlos III Health Institute; Rovi Pharmaceuticals Laboratories

Terminated

Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients

Diabetic Angiopathies | Foot Ulcer, Diabetic
Clinica Universidad de Navarra, Universidad de...
Rovi Pharmaceuticals Laboratories; Equipe Enervit

Completed

Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients

Overweight | Type-2 Diabetes

Spain
Fundacion para la Investigacion Biomedica del Hospital...
Rovi Pharmaceuticals Laboratories

Completed

Use of Bemiparine as a Prophylactic Antithrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction

Patients Undergoing Microvascular Surgery

Spain
Clinica Universidad de Navarra, Universidad de...
Laboratorio farmacéutico ROVI

Terminated

Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)

Cancer | Thrombosis

Spain, Romania
PT Novell Pharmaceutical Laboratories

Completed

A Bioequivalence Study of Two Azithromycin Tablet Formulations in Indonesian Healthy Subjects

Fasting

Indonesia
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

Functional Constipation in Children Ages 6-17 Years

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Merz Pharmaceuticals GmbH

Completed

Open-label Study of Safety and Tolerability of Memantine in Children With Autism

Autism | Pediatric Autism

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Opioid-Induced Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Merz Pharmaceuticals GmbH

Completed

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

Autism

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Constipation

Chronic Constipation

United States
Roxane Laboratories

Completed

Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions

Herpes

United States
Roxane Laboratories

Completed

Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions

Herpes

United States
Roxane Laboratories

Completed

Bioequivalency Study of Torsemide Tablets Under Fasting Conditions

Edema

United States
Roxane Laboratories

Completed

Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions

Infection

United States
Roxane Laboratories

Completed

Food Effect Study of Codeine Sulfate

Pain

United States
Roxane Laboratories

Completed

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions

Essential Hypertension

United States
Roxane Laboratories

Completed

Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions

Opioid-Related Disorders

United States
Roxane Laboratories

Completed

Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions

Seizures

United States
Roxane Laboratories

Completed

Comparative Bioavailability Study of Codeine Sulfate

Pain

United States
Roxane Laboratories

Completed

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions

Breast Cancer

United States
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

Hypertension

United States
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions

Trichomoniasis

United States
Roxane Laboratories

Completed

Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions

Epilepsy | Seizures

United States

3

Subscribe